Advertisement

Topics

MannKind Corporation Company Profile

18:23 EDT 19th September 2017 | BioPortfolio

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA(TM) and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of AFREZZA for the treatment of adults with Type 1 or Type 2 diabetes for the control of hyperglycemia. In March 2010, MannKind received a Complete Response to this NDA from the FDA requesting additional information. An End-of-Review meeting was held in June 2010 and MannKind is currently preparing its resubmission of the AFREZZA NDA. Other products in MannKind's pipeline include the cancer immunotherapy products MKC1106-PP and MKC1106-MT, which are currently in phase 1 clinical trials. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.


News Articles [135 Associated News Articles listed on BioPortfolio]

MannKind moves headquarters within California

MannKind announced that it has relocated its headquarters from Ventura, Calif., to Westlake Village, Calif. MannKind also has a manufacturing facility in Danbury, Conn.

MannKind Corp. Appoints Michael Castagna As CEO

WASHINGTON (dpa-AFX) - MannKind Corp. (MNKD) announced its Board appointed Michael Castagna as CEO, effective May 25, 2017. Castagna replaced Matthew Pfeffer, who served as both CEO and CFO since ...

Afrezza driving Mannkind results

Michael Castagna, new CEO of MannKind Corporation, stands in the company's Danbury, Conn., manufacturing facility on Tuesday, June 6, 2017. Michael Castagna, new CEO of MannKind Corporation, stand...

New MannKind CEO: Afrezza, global markets are key to...

Michael Castagna, new CEO of MannKind Corporation, stands in the company's Danbury, Conn., manufacturing facility on Tuesday, June 6, 2017. Michael Castagna, new CEO of MannKind Corporation, stand...

One Drop and MannKind team for inhalable insulin trial

Diabetes management platform developer One Drop is to feature in a new trial investigating MannKind’s inhalable insulin, Afrezza. Named the A-ONE study, the trial will couple the use of One Drop’...

Clinical trial launches for inhaled insulin, digital diabetes platform

MannKind Coroporation and One Drop announced the launch of a collaborative study of inhaled insulin and an integrated diabetes management platform, according to a press release from the companies. The...

MannKind Corp.: Nothing But Losses

MannKind - Afrezza Scripts Dip

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

The Need for Faster Insulin.

Considerable progress in treatment of diabetes has been made in the nearly 100 years following the discovery of insulin, and advances in insulin therapy have improved convenience, quality of life, ove...

Clinical Trials [0 Results]

None

Companies [173 Associated Companies listed on BioPortfolio]

MannKind Corporation

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its ...

Toshiba Corporation

Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultr...

MannKind

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product c...

Bruker Daltonics

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analy...

MannKind Corporation and Tolero Pharmaceuticals

Tolero is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat and cure cancer and other life-threatening diseases. Tolero has use...

More Information about "MannKind Corporation" on BioPortfolio

We have published hundreds of MannKind Corporation news stories on BioPortfolio along with dozens of MannKind Corporation Clinical Trials and PubMed Articles about MannKind Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MannKind Corporation Companies in our database. You can also find out about relevant MannKind Corporation Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record